Stay updated on Pembrolizumab for Meningioma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for Meningioma Clinical Trial page.

Latest updates to the Pembrolizumab for Meningioma Clinical Trial page
- Check3 days agoChange DetectedA banner notice about a lapse in government funding and related operating-status information was added; the revision was updated to v3.4.1 with new dates (2026-01-29, 2026-01-21, 2026-01), and the previous revision v3.4.0 was removed.SummaryDifference0.6%

- Check10 days agoChange DetectedUI/metadata updates include a new glossary display label, updated QC-related date fields (Last Update Submitted that Met QC Criteria and Last Update Posted), the No FEAR Act Data label, and a revision bump to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedRevision of Study Documents updated from v3.3.3 to v3.3.4; this appears to be a minor administrative update with no impact on eligibility criteria, trial results, or contacts. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check46 days agoChange DetectedAdded a Massachusetts Locations section listing study sites (Dana-Farber Cancer Institute and Massachusetts General Hospital). Removed the separate Massachusetts Locations subsection and updated the page revision to v3.3.3.SummaryDifference0.2%

- Check68 days agoChange DetectedRevision from v3.3.1 to v3.3.2, with no visible changes to study data or page layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check75 days agoChange DetectedPublications From PubMed description updated to say publications are automatically filled in from PubMed and may not be about the study, and the revision label updated to v3.3.1.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab for Meningioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for Meningioma Clinical Trial page.